In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin b therapy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2740-2746

  Phe, Kady ^a   Lee, Yuman ^b   McDaneld, Patrick M ^c   Prasad, Nishant ^d   Yin, Taijun ^e   Figueroa, Deborah A ^d   Musick, William L ^c   Cottreau, Jessica M ^a,e   Hu, Ming ^e   Tam, Vincent H ^a,e  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

^c Pharmacy Department Houston Methodist   (United States)

^d NEW YORK HOSPITAL QUEENS   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; COLISTIMETHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENTAMICIN; HYPERTENSIVE FACTOR; LOOP DIURETIC AGENT; POLYMYXIN B; VANCOMYCIN; ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID; POLYMYXIN;

ABDOMINAL INFECTION; ADULT; AGED; ANIMAL CELL; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CELL VIABILITY; COMPARATIVE STUDY; CYSTIC FIBROSIS; CYTOTOXICITY; FEMALE; HUMAN; IN VITRO STUDY; INFECTION; KIDNEY CELL; KIDNEY FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; URINARY TRACT INFECTION; WOUND INFECTION; ANALOGS AND DERIVATIVES; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; KIDNEY; MIDDLE AGED;

ADULT; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; COLISTIN; HUMANS; KIDNEY; MIDDLE AGED; POLYMYXINS; RETROSPECTIVE STUDIES;

EID: 84898606478     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02476-13     Document Type: Article

References (29)

1. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH. 2007. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn. Microbiol. Infect. Dis. 58: 99-104. http://dx.doi.org/10.1016/j.diagmicrobio.2006.11.014.
2. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717-3722. http://dx.doi.org/10.1128/AAC.00207- 10.
3. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. 2011. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn. Microbiol. Infect. Dis. 69:357-362. http://dx.doi.org/10.1016/j.diagmicrobio.2010.10.013.
4. Kwa A, Kasiakou SK, Tam VH, Falagas ME. 2007. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti. Infect. Ther. 5:811-821. http://dx.doi.org/10.1586/14787210.5.5.811.
5. Nord NM, Hoeprich PD. 1964. Polymyxin B and colistin. A critical comparison. N. Engl. J. Med. 270:1030-1035. http://dx.doi.org/10.1056/ NEJM196405142702002.
6. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care. 10:R27. http://dx.doi.org/10.1186/cc3995.
7. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. 2010. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35:194-199. http://dx.doi.org/10.1016/j.ijantimicag.2009.10. 005.
8. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-Associated nephrotoxicity in a large academic health system. Clin. Infect. Dis. 53:879-884. http://dx.doi.org/10.1093/cid/cir611.
9. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728. http://dx.doi.org/10.1086/599225.
10. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357.
11. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54:566-569. http://dx.doi.org/10.1093/jac/dkh369.
12. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob. Agents Chemother. 47: 2659-2662. http://dx.doi.org/10.1128/AAC.47.8.2659-2662.2003.
13. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. 2009. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn. Microbiol. Infect. Dis. 65:431-434. http://dx.doi.org/10.1016/j.diagmicrobio. 2009.07.018.
14. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294. http://dx.doi.org/10.1128/AAC. 01733-10.
15. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob. Agents Chemother. 56:4625-4629. http://dx.doi.org/ 10.1128/AAC.00280-12.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative w. 2004. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
17. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW. 2010. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54: 1160-1164. http://dx.doi.org/10. 1128/AAC.01446-09.
18. Wertheim H, Nguyen KV, Hara GL, Gelband H, Laxminarayan R, Mouton J, Cars O. 2013. Global survey of polymyxin use: a call for international guidelines. J. Glob. Antimicrob. Resist. 1:131-134. http://dx.doi.org/10.1016/j.jgar.2013. 03.012.
19. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L. 2003. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care. 7:R78-R83. http://dx.doi.org/10.1186/cc2358.
20. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. 2005. Colistin treatment in patients with ICU-Acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11:115-121. http://dx.doi.org/10.1111/j.1469-0691.2004. 01043.x.
21. Ramasubban S, Majumdar A, Das PS. 2008. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J. Crit. Care Med. 12:153-157. http://dx.doi.org/10.4103/0972-5229.45074.
22. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. 2012. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J. Infect. 65:80-87. http://dx.doi.org/10.1016/j.jinf.2012. 01.015.
23. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. 2006. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann. Pharmacother. 40:1939-1945. http://dx.doi.org/10.1345/aph.1H353.
24. Mendes CA, Cordeiro JA, Burdmann EA. 2009. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann. Pharmacother. 43:1948-1955. http://dx.doi.org/10.1345/aph.1M277.
25. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J. Antimicrob. Chemother. 65:2231-2237. http://dx.doi.org/10.1093/jac/dkq285.
26. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992. http://dx.doi.org/10.1093/jac/dkg468.
27. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 89:875-879. http://dx.doi.org/10.1038/clpt.2011.48.
28. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin. Infect. Dis. 57:1300-1303. http://dx.doi.org/10.1093/cid/cit453.
29. Pastewski AA, Caruso P, Parris AR, Dizon R, Kopec R, Sharma S, Mayer S, Ghitan M, Chapnick EK. 2008. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann. Pharmacother. 42:1177-1187. http://dx.doi.org/ 10.1345/aph.1K346.